448,958 Shares in MaxCyte, Inc. $MXCT Acquired by Man Group plc

Man Group plc purchased a new position in MaxCyte, Inc. (NASDAQ:MXCT) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 448,958 shares of the company’s stock, valued at approximately $552,000. Man Group plc owned about 0.42% of MaxCyte as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently modified their holdings of MXCT. Capricorn Fund Managers Ltd acquired a new stake in shares of MaxCyte during the 1st quarter valued at $5,760,000. Vitruvian Partners LLP acquired a new position in shares of MaxCyte in the 2nd quarter worth $6,203,328. BlackRock Inc. acquired a new stake in shares of MaxCyte during the second quarter worth $3,765,000. State Street Corp lifted its holdings in shares of MaxCyte by 4.0% during the fourth quarter. State Street Corp now owns 2,358,384 shares of the company’s stock valued at $3,655,000 after purchasing an additional 91,534 shares during the last quarter. Finally, AXA S.A. lifted its holdings in shares of MaxCyte by 123.2% during the second quarter. AXA S.A. now owns 2,202,378 shares of the company’s stock valued at $4,801,000 after purchasing an additional 1,215,481 shares during the last quarter. Institutional investors own 68.81% of the company’s stock.

MaxCyte Stock Down 0.8%

Shares of MaxCyte stock opened at $1.26 on Friday. MaxCyte, Inc. has a 12 month low of $0.64 and a 12 month high of $1.86. The stock has a market cap of $130.04 million, a PE ratio of -3.82 and a beta of 1.52. The business has a fifty day simple moving average of $1.24 and a 200-day simple moving average of $1.02.

MaxCyte (NASDAQ:MXCT) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.01. MaxCyte had a negative return on equity of 18.92% and a negative net margin of 114.77%.The firm had revenue of $6.50 million during the quarter, compared to the consensus estimate of $6.51 million. Analysts expect that MaxCyte, Inc. will post -0.25 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the company. Wall Street Zen raised MaxCyte from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings raised shares of MaxCyte from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 25th. Finally, BTIG Research reiterated a “neutral” rating on shares of MaxCyte in a report on Monday, August 24th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $5.00.

About MaxCyte

MaxCyte, Inc (NASDAQ: MXCT) is a clinical?stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical?scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.